Lytix Biopharma

Less than 1K followers

LYTIX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

11.13M

EBIT %

-861.64 %

P/E

-

Dividend yield-%

-

All

Press releases

ShowingAll content types

Press release11/19/2025, 7:23 AM

Redeye: Lytix Biopharma (Q3 Review) - Positive Clinical Readouts

Lytix Biopharma

Regulatory press release11/18/2025, 6:00 AM

Lytix Biopharma AS: Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy

Lytix Biopharma

Regulatory press release11/14/2025, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2025 Results Presentation

Lytix Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release11/11/2025, 2:27 PM

BioStock: Lytix Biopharmas onkolytiska immunterapi ruxotemitid visar starka fas II-data

Lytix Biopharma

Press release11/11/2025, 2:27 PM

BioStock: Lytix Biopharma’s oncolytic immunotherapy ruxotemitide shows strong phase II data

Lytix Biopharma

Regulatory press release11/11/2025, 6:00 AM

Lytix Biopharma AS: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital

Lytix Biopharma

Regulatory press release11/11/2025, 6:00 AM

LYTIX: Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital

Lytix Biopharma

Regulatory press release11/10/2025, 6:00 AM

Lytix Biopharma AS: New Phase II Study Data from Lytix Biopharma's Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide

Lytix Biopharma

Regulatory press release10/10/2025, 9:46 AM

LYTIX: Financial calendar

Lytix Biopharma

Regulatory press release10/8/2025, 5:05 AM

Lytix Biopharma AS: Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025

Lytix Biopharma

Regulatory press release9/1/2025, 5:55 PM

Lytix Biopharma AS: Grant of share options to management and key personnel

Lytix Biopharma

Press release8/29/2025, 10:51 AM

Redeye: Lytix Biopharma Q2 2025 - Extended Update

Lytix Biopharma

Regulatory press release8/28/2025, 5:07 AM

Lytix Biopharma AS: Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization

Lytix Biopharma

Regulatory press release8/21/2025, 12:08 PM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q2 2025 Results Presentation

Lytix Biopharma

Press release5/19/2025, 11:16 AM

Redeye: Lytix Biopharma Q1 2025 - Progress in NeoLIPA but Financial Weakness for Verrica

Lytix Biopharma

Regulatory press release5/15/2025, 5:05 AM

Lytix Biopharma AS: Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress

Lytix Biopharma

Regulatory press release5/9/2025, 5:10 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q1 2025 Results Presentation

Lytix Biopharma

Regulatory press release4/29/2025, 12:27 PM

Lytix Biopharma AS reshuffled its Board after the Ordinary General Meeting

Lytix Biopharma

Regulatory press release4/22/2025, 7:33 PM

Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair

Lytix Biopharma

Regulatory press release4/10/2025, 5:20 AM

Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025

Lytix Biopharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.